focus -WSS

focus

author：comprehensive 2025-09-06 04:14:25 - browse：3

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Megan Rapinoe shares emotional post following US Women's World Cup exit

hotspot

WSS

After Optum profits sink, UnitedHealth makes changes

Hospitals are dialing back on venture capital investing

After Optum profits sink, UnitedHealth makes changes

340B reform proposal comes out of Senate working group

Hospitals are dialing back on venture capital investing

A single Democrat is willing to weaken Medicare negotiation power

hotspot

focus

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Aspartame and sugar

Supreme Court strikes down use of affirmative action

Global cancer cases to surge 77% by 2050, WHO report says

Psychedelics group wrestles with new pharma identity

BMS, looking to build heart drug business, turns to AI for diagnosis

Wildfire smoke exposes gaps in outdoor worker protections

Judge sides with young activists in first

Dobbs anniversary: the lost opportunity of abortion as health care

340B reform proposal comes out of Senate working group

leisure time

Top private equity targets in 2023: cardiology, clinical trials, lasers

Biogen’s boardroom scandal saddles CEO with first crisis

Adopting new red light myopia treatments may be short

Mark Cuban is blaming the wrong people for high drug costs

Timeline: How the deadly wildfires took over Maui day by day

Surge in Apellis stock fueled by confidence in safety of its eye drug

focus

leisure time

hotspot

focus